Alignment Healthcare, Inc. Q3 FY2026 earnings call

• Claims System Migration: Completed migration to the FACETS claims adjudication system in July. While intended to improve speed and integrity, the transition caused volatility, leading to higher provider appeals and disputes that peaked in July but have stabilized since August.
• Cost Trends: Experienced elevated costs in skilled nursing facilities (SNF) and catastrophic cases during Q3. Management notes these trends are moderating as of September/October but is maintaining a prudent outlook for the remainder of the year.
• STAR Ratings: Maintained 4+ stars in six of seven eligible plans. The California HMO contract received a 3.5-star rating due to misses on triple-weighted measures (HAOS, Part B) and high industry cut points. Remediation efforts include data fixes, workflow changes, and increased provider engagement, operationalized for the 2026 cycle.
• Clinical & Operational Investments: Increased investments in clinical programs and payment integrity functions to control utilization and improve auto-adjudication. De-delegated institutional acute utilization management (UM) from IPAs in California, now ~80% complete, to regain control over inpatient costs.
• Strategic Positioning: Focus remains on executing current initiatives while preparing for 2027 growth targets of at least 20%, supported by strong broker relationships and new provider partnerships (e.g., Hoag Memorial, Estrana).

The provided transcript does not break down financial performance by specific product segments (e.g., HMO vs. SNP). The company reports consolidated health plan membership of 301,200 (up 31% YoY), driving total revenue of approximately $1.4 billion (up 37% YoY). Adjusted gross profit was $142 million with an adjusted Medical Benefit Ratio (MBR) of 89.5%. Adjusted SG&A was $120 million (8.9% of revenue). Adjusted EBITDA was $22 million.

• Q4 2026 Guidance: Membership no less than 305,000; Revenue no less than $1.32 billion; Adjusted Gross Profit no less than $104 million; Adjusted EBITDA no less than negative $28 million.
• Full Year 2026 Guidance: Revenue no less than $5.25 billion; Adjusted Gross Profit no less than $575 million; Adjusted EBITDA no less than $100 million.
• Revisions: Annual guidance has been lowered/prudently adjusted downward compared to previous expectations due to persistent cost headwinds (appeals, SNF, CAT cases).
• Assumptions: Q4 guidance assumes continuation of peak-level appeals/disputes and SNF/CAT costs without factoring in benefits from ongoing mitigation initiatives (payment integrity, clinical investments). SG&A expected to increase slightly due to AEP marketing and growth-related costs.

• Operational Execution Risk: Risks associated with the recent claims system migration (FACETS) causing processing volatility and delayed identification of high-cost claims.
• Medical Cost Volatility: Elevated and unpredictable cost trends in skilled nursing, catastrophic cases, and provider appeals/disputes impacting MBR.
• Regulatory/Star Rating Risk: Failure to maintain high STAR ratings (specifically the drop to 3.5 stars in CA HMO) could impact future Medicare Advantage payments and market competitiveness.
• Provider Relations: Potential friction or renegotiation demands from delegated IPAs and provider networks if STAR ratings remain low, though management reports collaborative remediation efforts.

Q: Analyst asked how the FACETS claims system migration contributed to higher cost trends. / A: CEO explained the migration created timing volatility and configuration issues, peaking in July. This led to a surge in provider appeals and disputes. While trends have stabilized since August, management remains prudent, assuming these elevated costs persist into Q4 despite visible improvement.

Q: Analyst inquired about 2027 bid positioning and membership diversification. / A: CEO stated bids were recalibrated against current trends, adjusting network choices and product growth speeds. They aim for 20% growth balancing margin expansion. Regarding diversity, they acknowledged heavy CA HMO concentration but are focusing on fixing STAR root causes rather than immediate tactical shifts, leveraging strong broker confidence despite the CA star downgrade.

Q: Analyst asked if Q4 MLR should be used as a baseline for 2027 projections. / A: CFO and CEO strongly advised against this, calling it a mistake. They emphasized that Q4 includes full burden of one-time transition costs and conservative assumptions. 2027 will benefit from run-rate improvements in payment integrity and clinical models, offering potential upside above the conservative Q4 run rate.

Q: Analyst asked about the de-delegation of UM and risk sharing strategies. / A: CEO detailed the strategic shift to reclaim inpatient UM control from IPAs (~80% done) to protect margins against global cap pressures. Future focus is on pre-service/outpatient UM integration, especially ex-California, to route members to high-performing providers efficiently, enhancing network utility regardless of contracting model.

Q: Analyst asked about the impact of the CA STAR downgrade on broker feedback and new provider negotiations. / A: CEO confirmed no negative impact on broker sentiment or early AEP sales due to long-standing trust. New partners like Hoag and Estrana are collaborating on STAR remediation. Management views this as a 'wake-up call' to realign with providers on quality metrics, viewing it as an opportunity to strengthen partnerships and fix underlying care delivery issues.